Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  Benzylpyridinium >  2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid

Basic information Safety Supplier Related

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Basic information

Product Name:
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid
Synonyms:
  • EVATANEPAG;CP-533536;CP 533536
  • CP-533536;CP 533536;CP533536
  • (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid
  • Evatanepag (CP-533536)
  • CS-2325
  • 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid
  • CP-533536
  • Evatanepag
CAS:
223488-57-1
MF:
C25H28N2O5S
MW:
468.57
Mol File:
223488-57-1.mol
More
Less

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Chemical Properties

storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
DMSO:32.0(Max Conc. mg/mL);68.29(Max Conc. mM)
form 
Solid
color 
White to off-white
More
Less

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid Usage And Synthesis

Uses

Evatanepag is an EP2 receptor selective prostaglandin E2 agonist that helps induce bone growth.

Definition

ChEBI: Evatanepag is a monocarboxylic acid.

in vivo

Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats[1].
Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice[2].
Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t1/2: 0.33 h)[1].

Animal Model:Rats[1]
Dosage:0.3, 1.0, 3.0 mg/kg
Administration:Directly injected into the marrow cavity of the tibia
Result:Dose-dependently increased in bone area, bone mineral content, bone mineral density.
Animal Model:HDM (house dust mite)-sensitized BALB/c mice[2]
Dosage:0.3 mg/kg, 3 mg/kg
Administration:Intranasal administration, from day1 to day4
Result:Prevented aeroallergen-driven increased RL (lung resistance) at 0.3 mg/kg.
Prevented the enhanced MC activity by approximately 48% at 3 mg/kg.

IC 50

EP2

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acidSupplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
HangZhou YuHao Chemical Technology Co., Ltd.
Tel
0571-82693216
Email
info@yuhaochemical.com
More
Less

2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(223488-57-1)Related Product Information